VAXCYTE, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
VAXCYTE, INC. (PCVX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $14.39 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-24
- VAXCYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-06-30 was $9.09, a 34.08% decline year-over-year.
- VAXCYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $13.97, a 80.82% decline year-over-year.
- VAXCYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-09-30 was $22.61, a 51.85% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-06-30 was $13.79, a 9.18% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $14.39, a 3.01% increase from fiscal 2024.
- VAXCYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $13.97, a 33.05% increase from fiscal 2023.
- VAXCYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $10.50, a 147.06% increase from fiscal 2022.
- VAXCYTE, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $4.25, a 30.77% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $14.39 10-K · filed 2026-02-24 | |||
| 2025-06-30 | $9.09 10-Q · filed 2025-08-06 | $13.00 10-Q · filed 2025-08-06 | ||
| 2025-03-31 | $13.97 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | $13.97 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $22.61 10-Q · filed 2024-11-05 | $14.84 10-Q · filed 2024-11-05 | ||
| 2024-06-30 | $13.79 10-Q · filed 2025-08-06 | $10.16 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $72.85 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $10.50 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $14.89 10-Q · filed 2024-11-05 | $11.33 10-Q · filed 2024-11-05 | ||
| 2023-06-30 | $12.63 10-Q · filed 2024-08-06 | $8.34 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $5.40 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $4.25 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $7.90 10-Q · filed 2023-11-06 | $6.06 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | $4.18 10-Q · filed 2023-08-08 | $3.64 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $3.18 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $3.25 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $3.91 10-Q · filed 2022-11-07 | $2.50 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $2.51 10-Q · filed 2022-08-08 | $2.10 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $1.82 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $1.88 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $1.60 10-Q · filed 2021-11-10 | $1.86 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $1.96 10-Q · filed 2021-08-11 | $1.95 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $1.94 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $1.46 10-K · filed 2021-03-29 | |||
| 2019-09-30 | $1.55 10-Q · filed 2020-11-12 | $1.55 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $1.06 10-Q · filed 2020-08-12 | $1.06 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $1.48 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |